Developing new and innovative treatments for patients is our mission here at Ipsen, and we will continue doing so, while delivering solid results across our three therapeutic areas: Oncology, Neuroscience and Rare Diseases.
As we move into 2020, our priorities remain the same:
- We will advance our pipeline through robust clinical development programs and additional business development opportunities
- We will drive our leadership positions in the highly competitive markets we are currently in
- We will nurture and grow our people, so we are able to give our best to patients
Focusing on these priorities has so far proven successful for Ipsen. In 2019 alone, we further strengthened our pipeline through promising data for Onivyde®, advanced studies for additional indications for Cabometyx® and developed new neurotoxins programs. We made great strides in building a leading Rare Diseases therapeutic area through the successful acquisition and integration of Clementia as well as our exclusive global in-license agreement with Blueprint Medicines. We also remain confident in bringing palovarotene to patients living with FOP as quickly as possible.
“As Ipsen’s CEO for the next few months, I am looking forward to another promising year ahead. Our position as a leading global biopharmaceutical company is strong, and we are now better placed to leverage the right opportunities that yield critical treatment options for patients with unmet medical needs,” said Aymeric Le Chatelier.
Our path forward is clear, and we remain committed to improving the lives of patients around the world affected by cancer, neurological and rare diseases.
